Review



precision x rad smart plus 225cx system  (Precision X-Ray)


Bioz Verified Symbol Precision X-Ray is a verified supplier
Bioz Manufacturer Symbol Precision X-Ray manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Precision X-Ray precision x rad smart plus 225cx system
    Precision X Rad Smart Plus 225cx System, supplied by Precision X-Ray, used in various techniques. Bioz Stars score: 97/100, based on 363 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/precision+x+rad+smart+plus+225cx+system/bio_rxiv__64898__2025__12__08__692634-30-5-10?v=Precision+X-Ray
    Average 97 stars, based on 363 article reviews
    precision x rad smart plus 225cx system - by Bioz Stars, 2026-08
    97/100 stars

    Images



    Similar Products

    precision x rad smart plus 225cx system  (Precision X-Ray)
    97
    Precision X-Ray precision x rad smart plus 225cx system
    Precision X Rad Smart Plus 225cx System, supplied by Precision X-Ray, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/precision+x+rad+smart+plus+225cx+system/bio_rxiv__64898__2025__12__08__692634-30-5-10?v=Precision+X-Ray
    Average 97 stars, based on 1 article reviews
    precision x rad smart plus 225cx system - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier
    precision x rad smart plus 225cx irradiator  (Precision X-Ray)
    97
    Precision X-Ray precision x rad smart plus 225cx irradiator
    (A) C57BL/6 and TLR9KO/C57BL/6 mice were injected intravenously with 1×10 6 CMM leukemia cells. Mice with established leukemia (0.5-1% of AML cells in blood) were treated 6 times daily with RO containing CSI2 (5mg/kg) or PBS. The first dose of treatment and/or without was combined with TMI irradiation at a dose of 4 (Gy) using Precision X-RAD SMART <t>Plus/225cx</t> (Precision X-Ray, CT, USA). (B, C) CMM leukemia progression monitored in blood using flow cytometric analysis. (D) Reduced spleen size (left) and weight (right) at the end of the study; (E) The percentages of CMM cells in spleen or BM as assessed using flow cytometry are not significantly different in TMI/CSI2-treated WT and TLR9KO mice. (F) The percentages of differentiating CD11b+ CMM leukemic cells in spleen or BM of TMI/CSI2-treated WT and TLR9KO mice. TLR9-deletion in the host reduces the recruitment of CD8+ T-cells (G) and Tregs (CD4+/Foxp3+) in spleen and bone marrow of TMI/CSI2-treated mice. Shown are means±SD, (n=3-6).
    Precision X Rad Smart Plus 225cx Irradiator, supplied by Precision X-Ray, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/precision+x+rad+smart+plus+225cx+system/bio_rxiv__2025__05__14__653587-39-21-26?v=Precision+X-Ray
    Average 97 stars, based on 1 article reviews
    precision x rad smart plus 225cx irradiator - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier
    precision x rad smart plus 225cx  (Precision X-Ray)
    97
    Precision X-Ray precision x rad smart plus 225cx
    (A) C57BL/6 and TLR9KO/C57BL/6 mice were injected intravenously with 1×10 6 CMM leukemia cells. Mice with established leukemia (0.5-1% of AML cells in blood) were treated 6 times daily with RO containing CSI2 (5mg/kg) or PBS. The first dose of treatment and/or without was combined with TMI irradiation at a dose of 4 (Gy) using Precision X-RAD SMART <t>Plus/225cx</t> (Precision X-Ray, CT, USA). (B, C) CMM leukemia progression monitored in blood using flow cytometric analysis. (D) Reduced spleen size (left) and weight (right) at the end of the study; (E) The percentages of CMM cells in spleen or BM as assessed using flow cytometry are not significantly different in TMI/CSI2-treated WT and TLR9KO mice. (F) The percentages of differentiating CD11b+ CMM leukemic cells in spleen or BM of TMI/CSI2-treated WT and TLR9KO mice. TLR9-deletion in the host reduces the recruitment of CD8+ T-cells (G) and Tregs (CD4+/Foxp3+) in spleen and bone marrow of TMI/CSI2-treated mice. Shown are means±SD, (n=3-6).
    Precision X Rad Smart Plus 225cx, supplied by Precision X-Ray, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/precision+x+rad+smart+plus+225cx+system/pmc12071099-63-27-31?v=Precision+X-Ray
    Average 97 stars, based on 1 article reviews
    precision x rad smart plus 225cx - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier
    precision x rad smart plus  (Precision X-Ray)
    97
    Precision X-Ray precision x rad smart plus
    (A) C57BL/6 and TLR9KO/C57BL/6 mice were injected intravenously with 1×10 6 CMM leukemia cells. Mice with established leukemia (0.5-1% of AML cells in blood) were treated 6 times daily with RO containing CSI2 (5mg/kg) or PBS. The first dose of treatment and/or without was combined with TMI irradiation at a dose of 4 (Gy) using Precision X-RAD SMART <t>Plus/225cx</t> (Precision X-Ray, CT, USA). (B, C) CMM leukemia progression monitored in blood using flow cytometric analysis. (D) Reduced spleen size (left) and weight (right) at the end of the study; (E) The percentages of CMM cells in spleen or BM as assessed using flow cytometry are not significantly different in TMI/CSI2-treated WT and TLR9KO mice. (F) The percentages of differentiating CD11b+ CMM leukemic cells in spleen or BM of TMI/CSI2-treated WT and TLR9KO mice. TLR9-deletion in the host reduces the recruitment of CD8+ T-cells (G) and Tregs (CD4+/Foxp3+) in spleen and bone marrow of TMI/CSI2-treated mice. Shown are means±SD, (n=3-6).
    Precision X Rad Smart Plus, supplied by Precision X-Ray, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/precision+x+rad+smart+plus+225cx+system/pm34767936-70-11-21?v=Precision+X-Ray
    Average 97 stars, based on 1 article reviews
    precision x rad smart plus - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) C57BL/6 and TLR9KO/C57BL/6 mice were injected intravenously with 1×10 6 CMM leukemia cells. Mice with established leukemia (0.5-1% of AML cells in blood) were treated 6 times daily with RO containing CSI2 (5mg/kg) or PBS. The first dose of treatment and/or without was combined with TMI irradiation at a dose of 4 (Gy) using Precision X-RAD SMART Plus/225cx (Precision X-Ray, CT, USA). (B, C) CMM leukemia progression monitored in blood using flow cytometric analysis. (D) Reduced spleen size (left) and weight (right) at the end of the study; (E) The percentages of CMM cells in spleen or BM as assessed using flow cytometry are not significantly different in TMI/CSI2-treated WT and TLR9KO mice. (F) The percentages of differentiating CD11b+ CMM leukemic cells in spleen or BM of TMI/CSI2-treated WT and TLR9KO mice. TLR9-deletion in the host reduces the recruitment of CD8+ T-cells (G) and Tregs (CD4+/Foxp3+) in spleen and bone marrow of TMI/CSI2-treated mice. Shown are means±SD, (n=3-6).

    Journal: bioRxiv

    Article Title: Targeted Irradiation and STAT3 Inhibition Reprogram the AML Microenvironment and Extend Survival: Toward Translational Immunoradiotherapy

    doi: 10.1101/2025.05.14.653587

    Figure Lengend Snippet: (A) C57BL/6 and TLR9KO/C57BL/6 mice were injected intravenously with 1×10 6 CMM leukemia cells. Mice with established leukemia (0.5-1% of AML cells in blood) were treated 6 times daily with RO containing CSI2 (5mg/kg) or PBS. The first dose of treatment and/or without was combined with TMI irradiation at a dose of 4 (Gy) using Precision X-RAD SMART Plus/225cx (Precision X-Ray, CT, USA). (B, C) CMM leukemia progression monitored in blood using flow cytometric analysis. (D) Reduced spleen size (left) and weight (right) at the end of the study; (E) The percentages of CMM cells in spleen or BM as assessed using flow cytometry are not significantly different in TMI/CSI2-treated WT and TLR9KO mice. (F) The percentages of differentiating CD11b+ CMM leukemic cells in spleen or BM of TMI/CSI2-treated WT and TLR9KO mice. TLR9-deletion in the host reduces the recruitment of CD8+ T-cells (G) and Tregs (CD4+/Foxp3+) in spleen and bone marrow of TMI/CSI2-treated mice. Shown are means±SD, (n=3-6).

    Article Snippet: The first dose of treatment, with or without RO, was combined with TMI at a dose of 4 Gy using the Precision X-RAD SMART Plus/225cx irradiator (Precision X-Ray, CT, USA).

    Techniques: Injection, Irradiation, Flow Cytometry